CTI 205
Alternative Names: CTI-205Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Cellics Therapeutics
- Class Antirheumatics
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 20 Aug 2020 CTI 205 is available for licensing as of 20 Aug 2020. https://cellics.com/
- 20 Aug 2020 Preclinical trials in Rheumatoid arthritis in USA (unspecified route) (Cellics therapeutics pipeline August 2020)